Novel Workflow Closes the Gap in Detecting 5q-Spinal Muscular Atrophy
In their tailored 5q-SMA variant detection workflow published in the Journal of Neuromuscular Diseases investigators were able to more accurately identify patients with 5q-SMA
“The latest treatments have shown that early intervention can significantly improve clinical outcomes, so it is important to diagnose 5q-SMA early,” explained lead investigator Angela Abicht, MD, Medical Genetics Center and Department of Neurology, Friedrich-Baur-Institute, LMU Klinikum Munich.
In 96% of cases 5q-SMA is caused by a homozygous deletion of the SMN1 gene (loss of both alleles). However, around 4% of patients carry only a SMN1 deletion and a single-nucleotide variant (SNV) on the other allele.
Short-read next-generation sequencing (s-rNGS), commonly applied for whole-exome sequencing, is generally unable to detect individuals with 5q-SMA. The underlying reason is that the gene responsible for this condition, SMN1, possesses a nearly identical but non-functional copy, called SMN2. Thus, typical bioinformatics algorithms encounter difficulties when attempting to accurately assign the read sequences to either gene. Unambiguous reads are randomly mapped to a region and then assigned a low mapping quality, which leads to their exclusion by variant callers. Therefore, identification of a deleted or altered SMN1 gene through a standard bioinformatics pipeline is not possible.
Investigators retrospectively analyzed two cohorts of patients who underwent diagnostic s-rNGSbased exome analysis within a 12-month period between November 2021 and November 2022. Cohort 1 consisted of 1,684 patients with a neuromuscular phenotype as evidenced by the presence of at least one of the Human Phenotype Ontology (HPO) phenotypes or its direct descendants: muscular abnormality or peripheral neuropathy. Cohort 2 consisted of the fetal samples from 260 patients who underwent exome sequencing as part of prenatal diagnostics within the one-year period.
In their tailored 5q-SMA variant detection workflow, investigators used a bioinformatics pipeline that was “SMN2-masked,” i.e., for SMN1, the paralogous regions that comprise SMN2 “hidden” in the reference genome. Consequently, all NGS reads that were generated were forced to map only to SMN1. In a subsequent SMN1/2 variant filtering workflow, they used the allele frequencies of a unique SMN1 variant to identify deletions of SMN1 that were homozygous and single nucleotide variants of SMN1 that were homozygous (consisting of two identical alleles at a given locus), heterozygous (consisting of two different alleles at a locus), or hemizygous (consisting of only a single copy of a particular gene).
The application of this new workflow revealed a diagnosis of 5q-SMA in nine patients with neuromuscular phenotypes in cohort 1. One patient with 5q-SMA was identified in cohort 2.
This study demonstrates that it is possible to reliably identify patients with 5q-SMA within a diagnostic whole exome analysis by using a tailored 5q-SMA variant detection workflow. This result is significant because investigators identified several patients who were not thought to have 5q-SMA because they did not present the typical clinical picture of SMA. In addition, two patients (a 48-year-old woman and a four-month-old infant) carried biallelic single nucleotide variants of SMN1.
Co-lead investigator Teresa Neuhann, MD, Medical Genetics Center, Munich, added, “This was an exciting finding because in all patients described previously, 5q-SMA was either caused by a homozygous deletion of SMN1 (in 96% of cases) or by a SMN1 deletion and a single-nucleotide variant on the other allele (in 4% of cases). In both patients, the genetic diagnosis was made after a diagnostic odyssey as the initial clinical diagnosis of 5q-SMA was not confirmed by standard SMA testing with multiplex ligation-dependent probe amplification (MLPA).”
s-rNGS is the current standard test in human genetics. It offers significant diagnostic advantages compared to former single gene Sanger sequencing. However, clinicians must be aware of gaps, particularly in detection of 5q-SMA, an important treatable disorder for which some countries have recently implemented newborn screening.
“To bridge the gap, diagnostic laboratories should utilize adopted pipelines and workflows in short-read sequencing,” commented Dr. Abicht. “Clinicians, on the other hand, can bridge the gap by proceeding with SMN1 sequencing in case the absence of a hetero- or homozygous SMN1 deletion is indicated by MLPA or real-time PCR methods, but the clinical evidence still strongly points to SMA.”
SMA is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot respond to signals from the nerves, they atrophy — weaken and shrink — from inactivity. 5q-SMA is one of the most common types of SMA with a frequency of approximately one in ten thousand worldwide. SMA patients are stratified into three groups: non-sitters, sitters, and walkers. Currently approved disease modifying therapies, which include nusinersen, risdiplam, and onasemnogene abeparvovec, require early, accurate genetic diagnosis of 5q-SMA to determine and initiate the most appropriate treatment.
# # #
NOTES FOR EDITORS
“Closing the Gap - Detection of 5q-Spinal Muscular Atrophy by Short-Read Next-Generation Sequencing and Unexpected Results in a Diagnostic Patient Cohort,” by Stephanie Kleinle, Veronika Scholz, Anna Benet-Pagés, Tobias Wohlfrom, Stefanie Gehling, Florentine Scharf, Simone Rost, Eva-Christina Prott, Susanne Grinzinger, Anna Hotter, Verena Haug , Sabine Niemeier, Lucia Wiethoff-Ubrig, Tim Hagenacker, Klaus Goldhahn, Arpad von Moers, Maggie C. Walter, Peter Reilich, Katja Eggermann, Florian Kraft, Ingo Kurth, Hannes Erdmann, Elke Holinski-Feder, Teresa Neuhann, and Angela Abicht (https://doi.org/10.3233/JND-221668), Journal of Neuromuscular Diseases, Volume 10, issue 5. The article is openly available at https://content.iospress.com/articles/journal-of-neuromuscular-diseases….
Copies of this paper are also available to credentialed journalists upon request. Please contact Diana Murray, IOS Press, at +1 718-640-5678 or firstname.lastname@example.org for the full text of the article or additional information. Journalists who wish to interview the authors should contact Angela Abicht, MD, at email@example.com.
ABOUT THE JOURNAL OF NEUROMUSCULAR DISEASES (JND)
The Journal of Neuromuscular Diseases facilitates progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis, and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias, and myositis). The journal publishes research reports, reviews, and short communications. Guided by Editors-in-Chief Carsten G. Bönnemann (National Institute of Neurological Disorders and Stroke, NIH) and Hanns Lochmüller (Children’s Hospital of Eastern Ontario Research Institute), the journal is dedicated to providing an open forum for original research in basic science, translational, and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases. www.iospress.com/journal-of-neuromuscular-diseases
ABOUT IOS PRESS
IOS Press is an international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation) and computer sciences (including artificial intelligence, data science, and semantic web). In addition, we offer specialized services that support scientific advancement. www.iospress.com